Programme NVHG 2024

Thursday September 19, 2024

Morning session 1 (9:15-11:00)

Welcome - Prof. dr. Mieke van Haelst

A Historical view of Human genetics

o   The history of the NVHG and the Simons fonds - Prof. dr. J.K. (Hans Kristian) Ploos van Amstel

o   The discovery of the Fragile X Syndrome gene – Dr. J. M. H. (Annemieke) Verkerk

Morning Session 2 (11:00-12:40)

From the past to the future: the human genome in health and disease

o   Genetic research among descendants of enslaved individuals – Dr. R.L.O. (Arwin) Ralf

o   European joint efforts for Rare Disease Diagnostic Research – Prof. dr. L. E. L. M. (Lisenka) Vissers

o   EU-1+MG: the Genome of Europe – Prof .dr. A.G. (André) Uitterlinden

o   Polygenic Risk Factors in Breast Cancer – Prof.dr.ir. M.K (Marjanka) Schmidt
 
Lunch (12:40-14:00)

Afternoon Session 1 (14:00-15:00)

Galjaard Lecture
Prof. dr. Dorret Boomsma

Poster blitz (15:00-15:30)

Coffee break/poster viewing (15:30-16:15)
 

Afternoon Session 2 (16:15- 17:45)

12 Selected abstracts

Public debate session (17:45-19:00)

Genetic Risk Scores everywhere!

In this informal session we aim to demystify the true value of genetic risk scores and empower you to take the initiative in their application. We will use polls, metaphors, case studies and debate to detach from the narrow focus on diseases and instead, explore the broader implications of risk scores in various contexts. We will debate the conditions and prerequisites necessary for each metaphor to hold true in the realm of genetic risk scores.

Evening Session (19.30 - 0.00)

Dinner and party

Friday September 20, 2024

Morning Session 1 (8:30-10:45)

Negative WES: what next? (Joint VKGL/VKGN session)

Coffee break (10:45-11:15)

Morning session 2 (11:15-12:40)

Technological innovations

o   The impact of technology; a historical perspective – Prof. dr. J.T. (Johan) den Dunnen

o   Interpretation of noncoding variants – Dr. T.S. (Stefan) Barakat

o   Sequence-based prediction models –  Dr. A. (Anshul) Kundaje

Lunch (12:40-13:00)

Poster session (13:00-14:00)

Keynote lecture (14:00-14:50)

o   The T2T project – Prof. dr. E.E. (Evan) Eichler

Afternoon Session 2 (14:50-16:15)

Gene Therapy: Opportunities and Challenges

o   In vivo gene editing of Hereditary Angioedema – Dr. D.A. (Danny) Cohn

o   Sickle Cell Anemia – Prof. dr. F.J.T. (Frank) Staal

o   Gene therapy in neurodevelopmental disorders - Prof. dr. C.D.M. (Clara) van Karnebeek

Ceremonial session (16.15-16.30h)